Ets‐1 controls breast cancer cell balance between invasion and growth

Ets‐1 overexpression in human breast cancers is associated with invasiveness and poor prognosis. By overexpressing Ets‐1 or a dominant negative mutant in MMT breast cancer cells, we previously highlighted the key role of Ets‐1 in coordinating multiple invasive features of these cells. Interestingly, we also noticed that Ets‐1 decreased the density of breast cancer cells cultured in three‐dimensional extracellular matrix gels. The 3D context was instrumental to this phenomenon, as such downregulation was not observed in cells grown on two‐dimensional plastic or matrix‐coated dishes. Ets‐1 overexpression was deleterious to anchorage‐independent growth of MMT cells in soft agar, a standard model for in vitro tumorigenicity. The relevance of this mechanism was confirmed in vivo, during primary tumor growth and in a metastatic assay of lung colonization. In these models, Ets‐1 was associated with epithelial‐to‐mesenchymal transition features and modulated the ratio of Ki67‐positive cells, while hardly affecting in vivo apoptotic cell death. Finally, siRNA‐mediated knockdown of Ets‐1 in human breast cancer cell lines also decreased colony growth, both in anchorage‐independent assays and 3D extracellular matrix cultures. These in vitro and in vivo observations shed light on an unsuspected facet of Ets‐1 in breast tumorigenesis. They show that while promoting malignancy through the acquisition of invasive features, Ets‐1 also attenuates breast tumor cell growth and could therefore repress the growth of primary tumors and metastases. This work also demonstrates that 3D models may reveal mechanisms of tumor biology that are cryptic in standard 2D models.

[1]  J. Tentler,et al.  Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism , 2011, Molecular Cancer.

[2]  D. Larsimont,et al.  Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51 , 2009, Oncogene.

[3]  M. Pawlita,et al.  High‐throughput SNP‐based authentication of human cell lines , 2013, International journal of cancer.

[4]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[5]  A. Furlan,et al.  Ets‐1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment , 2008, Journal of cellular physiology.

[6]  A. Giese Glioma invasion--pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. , 2003, Acta neurochirurgica. Supplement.

[7]  Bernard Vandenbunder,et al.  Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model , 2003, Oncogene.

[8]  V. Firlej,et al.  Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription , 2008, Journal of Cell Science.

[9]  T. Nakayama,et al.  Expression of the ets-1 Proto-Oncogene in Human Colorectal Carcinoma , 2001, Modern Pathology.

[10]  J. Tentler,et al.  ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells , 2004, Oncogene.

[11]  R. Weinberg,et al.  Adaptation versus selection: the origins of metastatic behavior. , 2007, Cancer research.

[12]  Kenneth M. Yamada,et al.  Direct comparisons of the morphology, migration, cell adhesions, and actin cytoskeleton of fibroblasts in four different three-dimensional extracellular matrices. , 2011, Tissue engineering. Part A.

[13]  B. Vandenbunder,et al.  The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. , 1998, Journal of cell science.

[14]  Xin-hua Liang,et al.  EMT: A new vision of hypoxia promoting cancer progression , 2011, Cancer biology & therapy.

[15]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[16]  K. Shirato,et al.  Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. , 2001, Biochemical and biophysical research communications.

[17]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[18]  I. Sekine,et al.  Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. , 2005, Histology and histopathology.

[19]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[20]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[21]  Kornelia Polyak,et al.  Heterogeneity in breast cancer. , 2011, The Journal of clinical investigation.

[22]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[23]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Vandenbunder,et al.  Expression of c-ets-1 and uPA genes is associated with mammary epithelial cell tubulogenesis or neoplastic scattering. , 1996, The International journal of developmental biology.

[25]  M. Aumercier,et al.  Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function. , 2010, The Biochemical journal.

[26]  Jun Yao,et al.  Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.

[27]  John S. Condeelis,et al.  Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors , 2004, Cancer Research.

[28]  B. Vandenbunder,et al.  The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors in human fibroblasts. , 1996, Experimental cell research.

[29]  Gerhard Christofori,et al.  Mouse models of breast cancer metastasis , 2006, Breast Cancer Research.

[30]  David P Turner,et al.  Prostate-Derived ETS Factor Regulates Epithelial-to-Mesenchymal Transition through Both SLUG-Dependent and Independent Mechanisms. , 2011, Genes & cancer.

[31]  T. Alber,et al.  Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix. , 1995, Science.

[32]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[33]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[34]  P. Wade,et al.  Yin Yang 1 Regulates the Expression of Snail through a Distal Enhancer , 2009, Molecular Cancer Research.

[35]  C. Holterman,et al.  ETS-1 oncogenic activity mediated by transforming growth factor alpha. , 2010, Cancer research.

[36]  Stephanie I. Fraley,et al.  A distinctive role for focal adhesion proteins in three-dimensional cell motility , 2010, Nature Cell Biology.

[37]  B. Vandenbunder,et al.  The ETS1 transcription factor is expressed during epithelial-mesenchymal transitions in the chick embryo and is activated in scatter factor-stimulated MDCK epithelial cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[39]  R. Palmqvist,et al.  Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers , 1999, British Journal of Cancer.

[40]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Wernert,et al.  ETS transcription factors and prostate cancer: the role of the family prototype ETS-1 (review). , 2012, International journal of oncology.

[42]  S. Kiriakidis,et al.  The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. , 2008, Mini reviews in medicinal chemistry.

[43]  Kenneth M. Yamada,et al.  Modeling Tissue Morphogenesis and Cancer in 3D , 2007, Cell.

[44]  G. Peters,et al.  Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence , 2001, Nature.

[45]  Ioanna G Maroulakou,et al.  Expression and function of Ets transcription factors in mammalian development: a regulatory network , 2000, Oncogene.

[46]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[47]  B. Vandenbunder,et al.  Constitutive expression of the DNA-binding domain of Ets1 increases endothelial cell adhesion and stimulates their organization into capillary-like structures , 2000, Oncogene.